The sponsor of the study is NMD Pharma A/S. If you’re living with Charcot-Marie-Tooth (CMT) disease, specifically CMT1 or CMT2 subtypes you may be eligible to participate in an exciting new clinical trial. NMD Pharma, a biotechnology company, has received approval...
Mario Bortolozzi, Ph. D. I am an associate Professor in Biophysics at the Department of Physics and Astronomy “G. Galilei” at the University of Padua in Italy. Following my studies in Physics at the same university, I earned my doctoral degree in...
The TIN CUP for CMT Therapies for Inherited Neuropathies (TIN) is a fully accredited 501(C)3 nonprofit whose sole focus is dedicated to identifying and advancing research and projects that bring solutions and treatments to Charcot-Marie-Tooth patients....
Email from CMT Patient from June 2023 Hello Mr. O’Donnell, It is a pleasure to be put in touch with you. I am a 39 year old man with 1A who has been working with Mike for about a year. Prior to working with him, I had a six year period of living with constant...
Physical Exercise study published in September 2021 issue of Experimental Neurology. The results of a TIN-sponsored study to determine the effects of exercise on the progression of CMT1X, using a mouse model of CMT1X, have now been published as the cover article in...
Therapies for Inherited Neuropathies team meets a key milestone and advances the development of therapeutics antibodies for the treatment of CMT1X. The laboratories of Rudolf Martini and Richard Stanley have previously reported the discovery of a novel biological...
